ArticleExperimental and therapeutic medicine2021

PI3K inhibition sensitizes EGFR wild-type NSCLC cell lines to erlotinib chemotherapy.

Xin Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.